Quantcast
Last updated on April 23, 2014 at 21:24 EDT

Latest ViaCyte Inc. Stories

2012-10-26 07:23:59

SAN DIEGO, Oct. 26, 2012 /PRNewswire/ -- ViaCyte, Inc., a leading regenerative medicine company developing a transformative cell therapy for treatment of diabetes, announced today that it has received a $10.1 million Strategic Partnership Award from the California Institute for Regenerative Medicine (CIRM). (Logo: http://photos.prnewswire.com/prnh/20121026/LA00871LOGO-a) (Logo: http://photos.prnewswire.com/prnh/20121026/LA00871LOGO-b) ViaCyte's innovative stem cell-based therapy for...

2012-06-15 02:25:23

SAN DIEGO, June 15, 2012 /PRNewswire/ -- ViaCyte, Inc. today announced the appointment of seasoned entrepreneur, Paul Laikind, Ph.D., as President & Chief Executive Officer. Allan Robins, Ph.D., who was serving as Acting CEO, will continue in his role as Vice President & Chief Technology Officer. ViaCyte is a leading pre-clinical company developing a novel cell therapy product for the treatment of insulin dependent diabetes. Dr. Laikind brings over 25 years of leadership experience...

2011-08-09 05:00:00

SAN DIEGO, Aug. 9, 2011 /PRNewswire/ -- ViaCyte, Inc. today announced changes to its executive management team, including the appointment of Allan Robins, Ph.D., as Acting Chief Executive Officer, and the promotion of Kevin D'Amour, Ph.D., to Chief Scientific Officer. Robins continues to serve as Vice President and Chief Technology Officer, and his appointment as acting CEO follows the departure of President and Chief Executive Officer John West who resigned for personal reasons. West...

2011-06-15 12:51:00

SAN DIEGO, June 15, 2011 /PRNewswire/ -- ViaCyte, Inc. today announced the appointment of Michael J. Scott, Ph.D. as Vice President, Device Research and Development, reporting to John West, President and Chief Executive Officer. In this capacity, Dr. Scott will oversee all device development and manufacturing activities, including design, engineering, and testing. Dr. Scott will also contribute to regulatory matters in the device area and to the overall leadership and strategic direction...

2011-05-13 12:05:00

SAN DIEGO, May 13, 2011 /PRNewswire/ -- ViaCyte, Inc., a preclinical cell therapy company focused on diabetes, today announced the appointment of Anthony ("Tony") Gringeri as Chief Development Officer. Dr. Gringeri brings to ViaCyte more than 20 years of experience successfully leading product development and strategic partnering. His track record includes biologics and gene therapies, which were new technologies to both U.S. and European regulators at the time of their development. Dr....

2011-04-13 07:00:00

MADISON, Wis., April 13, 2011 /PRNewswire/ -- Cellular Dynamics International (CDI), the world's largest producer of tissue cells derived from human induced pluripotent stem cell (iPSC) lines, today announced it has strengthened its intellectual property (IP) portfolio by licensing patented definitive endoderm differentiation technology from ViaCyte, Inc., a stem cell company focused on diabetes therapy. CDI will apply this patented methodology in the development and production of...

2010-05-05 20:18:00

SAN DIEGO, May 5 /PRNewswire/ -- ViaCyte, Inc., a preclinical stage stem cell engineering company focused on diabetes, announced today that it has received three additional U.S. Patents: On April 13, the Company was granted U.S. Patent 7,695,963, entitled "Methods for Increasing Definitive Endoderm Production". Methods described in this patent can improve the yield in manufacturing of definitive endoderm and also cells derived from it. On April 13, the Company was also granted U.S....

2010-05-05 20:13:00

SAN DIEGO, May 5 /PRNewswire/ -- Novocell, Inc., a preclinical stage stem cell engineering company focused on diabetes, announced today the Company's shareholders and Board of Directors approved a name change to ViaCyte, Inc. The name ViaCyte retains the Company's identity as a leading cell therapy company, as "-cyte" is derived from the Greek "kytos," which means cell. As the Company is moving towards the market, clear and unambiguous brand recognition is increasingly important. With...